Guangzhou Innogen Pharmaceutical Group (Innogen-B) released its first post-IPO annual results, highlighting the transition from pure R&D to simultaneous development and commercialisation.

Revenue and margins • First-time revenue reached RMB131.51 million in 2025, entirely from the February launch of Core Product Efsubaglutide Alfa for type-2 diabetes (T2D) in mainland China and the September launch in Macau. • Cost of sales was RMB14.45 million, producing a gross profit of RMB117.06 million and an 89.0% gross margin; the margin reflects the accounting treatment whereby pre-launch production costs were expensed as R&D.

Profitability • Loss before tax expanded to RMB341.36 million from RMB174.69 million in 2024. • Key drivers were a more than doubling of R&D expenses to RMB205.78 million, driven by process optimisation, expanded clinical trials in obesity and overseas studies, and higher raw-material spending. • Selling and distribution expenses jumped to RMB176.65 million (2024: RMB2.39 million) as commercial activities scaled up; headcount in the sales team increased from 5 to 89. • Administrative costs fell 8% to RMB77.40 million due to lower personnel expenses.

Balance-sheet highlights • Cash and cash equivalents stood at RMB969.09 million, supported by August 2025 IPO proceeds (net HKD645.20 million; HKD39.30 million utilised). • Net assets increased to RMB1.05 billion, while the gearing ratio rose to 33% on higher short-term bank borrowings of RMB150.26 million. • Current assets grew to RMB1.48 billion, outweighing current liabilities of RMB504.58 million, giving net current assets of RMB974.40 million.

Operational milestones • Efsubaglutide Alfa gained NRDL inclusion for adult T2D in December, effective 1 January 2026, and was cited in China’s 2025 primary-care diabetes guidelines. • Phase III enrolment for obesity/overweight in China was completed; topline data are expected by end-2026. Phase II obesity study in Australia finished enrolment in November 2025, evaluating weekly, bi-weekly and monthly dosing. • IND approval for metabolic dysfunction-associated steatohepatitis (MASH) was secured in both the US and China; early-stage fusion-protein programs are under way. • An AI-enabled drug-discovery platform and next-generation ultra-long-acting formulations (targeting three- to six-month dosing) were initiated. • Companion-animal indications advanced, with a veterinary clinical trial for diabetic pets accepted in early 2026.

Outlook for 2026 Management targets full-year ramp-up of T2D sales, broader hospital coverage after NRDL inclusion, Hong Kong launch preparation, and pre-launch work for the obesity indication pending Phase III results. Global expansion will focus on Hong Kong, Southeast Asia, Latin America and further strategic partnerships.